BioMagnetic Solutions Revenue and Competitors
Estimated Revenue & Valuation
- BioMagnetic Solutions's estimated annual revenue is currently $2M per year.
- BioMagnetic Solutions's estimated revenue per employee is $155,000
Employee Data
- BioMagnetic Solutions has 13 Employees.
- BioMagnetic Solutions grew their employee count by -41% last year.
BioMagnetic Solutions's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Chief Commercial Officer (CCO) & Co-Founder | Reveal Email/Phone |
2 | Chief Operating Officer | Reveal Email/Phone |
3 | Chief Scientific Officer | Reveal Email/Phone |
4 | Chief Scientific Officer | Reveal Email/Phone |
5 | Director Quality | Reveal Email/Phone |
6 | Laboratory Manager | Reveal Email/Phone |
BioMagnetic Solutions Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.4M | 9 | -10% | N/A | N/A |
#2 | $7.1M | 46 | 77% | N/A | N/A |
#3 | $14.4M | 93 | 27% | N/A | N/A |
#4 | $0.9M | 6 | 0% | N/A | N/A |
#5 | $1.6M | 10 | 43% | N/A | N/A |
#6 | $11.5M | 74 | 6% | N/A | N/A |
#7 | $0.9M | 11 | 22% | N/A | N/A |
#8 | $3.7M | 24 | -8% | N/A | N/A |
#9 | $2M | 13 | 18% | N/A | N/A |
#10 | $9.3M | 60 | 2% | N/A | N/A |
What Is BioMagnetic Solutions?
BioMagnetic Solutions (BioMag) is launching X-GRAFFE system, a state of the art immunomagnetic Cell Selection system for CAR-T cell & Gene Therapy (CGT) product mfg. X-GRAFFE will revolutionize the CGT cell selection process with its ultra high-performance, very rapid, gentle process & clean sheet of paper design & mkt. proven Ferrofluids. BioMag's X-GRAFFE Clinical-Scale Cell Selection system & nano-magnetic ferrofluids very rapidly yet very gently isolate cell subsets for CAR-T cell & gene therapy (GT) product mfg. X-GRAFFE is an elegant, closed system w/an array of patent-pending protocols & hardware. X-GRAFFE isolates CD34+ stem cells for GT & cell processing mfg. BioMag partners for its complementary array of cGMP mAbs, cytokines & CGT mfg. reagents. Founded in 2012 by Paul A. Liberti, PhD, BioMagnetic Solutions has a 30+ year history pioneering immuno-magnetic cell selection systems. Prior to BioMag, Liberti founded Immunicon (NASDAQ: IMMC) where he developed the Ferrofluids & immunomagnetic systems for CELLSEARCH® - the only FDA-approved Circulating Tumor Cell (CTC) assay that J&J/Janssen acq'd in 2008. BioMag's X-GRAFFE system leverages BioMag's market-tested** proprietary 6th-gen immunomagnetic Ferrofluids. BioMag also provides an array of proprietary cell selection reagents to the research market to scientists worldwide. Having pioneered Ferrofluid development & the design & mfg. of novel magnetic platform technologies for cell selection via our Immunicon DNA, BioMag brings 30+ cutting-edge R&D problem-solving years, IP & innovation to the design, synthesis & manufacture of Ferrofluids for path-breaking novel multi-parameter bio-magnetic selection systems. * CELLSEARCH® remains the only FDA-approved CTC assay for isolating & characterizing CTC - **16 years since its 2004 Immunicon introduction. CELLSEARCH© was acquired by J&J's Janssen Oncology SBU (formerly J&J's Veridex SBU). CELLSEARCH® is now owned by Menarini's Silicon Biosystems (2018).
keywords:N/A
N/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
-41%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in State College
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.2M | 14 | 133% | N/A |
#2 | $1.4M | 17 | -6% | N/A |
#3 | $2M | 20 | 18% | N/A |
#4 | $2M | 20 | -9% | N/A |
#5 | $1.6M | 21 | -28% | $10M |